Loading...
Drotrecogin alfa (activated): real-life use and outcomes for the UK
INTRODUCTION: In March 2001, the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study were published, which indicated a 6.1% absolute reduction in 28-day mortality. Drotrecogin alfa (activated; DrotAA) was subsequently approved for use in patient...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2008
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2447613/ https://ncbi.nlm.nih.gov/pubmed/18430215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc6879 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|